Fort Washington Investment Advisors Inc. OH held its stake in Sanofi (NYSE:SNY) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 90,563 shares of the company’s stock at the end of the 2nd quarter. Fort Washington Investment Advisors Inc. OH’s holdings in Sanofi were worth $4,339,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Harbour Capital Advisors LLC bought a new position in Sanofi in the 1st quarter worth about $113,000. Parallel Advisors LLC grew its position in Sanofi by 42.5% in the 2nd quarter. Parallel Advisors LLC now owns 2,934 shares of the company’s stock worth $139,000 after purchasing an additional 875 shares during the last quarter. Bronfman E.L. Rothschild L.P. grew its position in Sanofi by 142.8% in the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 3,567 shares of the company’s stock worth $171,000 after purchasing an additional 2,098 shares during the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC grew its position in Sanofi by 6,188.3% in the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 3,773 shares of the company’s stock worth $171,000 after purchasing an additional 3,713 shares during the last quarter. Finally, Proficio Capital Partners LLC grew its position in Sanofi by 95.8% in the 1st quarter. Proficio Capital Partners LLC now owns 4,265 shares of the company’s stock worth $210,000 after purchasing an additional 2,087 shares during the last quarter. Hedge funds and other institutional investors own 9.33% of the company’s stock.
In related news, major shareholder Sanofi purchased 60,595 shares of the business’s stock in a transaction dated Wednesday, August 23rd. The shares were acquired at an average cost of $478.98 per share, for a total transaction of $29,023,793.10. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 1.00% of the company’s stock.
Several research firms have commented on SNY. Cowen and Company restated a “market perform” rating and issued a $52.00 target price (up previously from $46.00) on shares of Sanofi in a research report on Tuesday, August 1st. BidaskClub upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Saturday, August 5th. HSBC Holdings plc upgraded shares of Sanofi from a “reduce” rating to a “hold” rating in a research report on Wednesday, August 30th. Argus upped their target price on shares of Sanofi from $50.00 to $55.00 and gave the stock a “buy” rating in a research report on Friday, June 9th. Finally, Zacks Investment Research raised shares of Sanofi from a “hold” rating to a “buy” rating and set a $55.00 price target for the company in a research note on Friday, June 2nd. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and five have assigned a buy rating to the company. Sanofi has a consensus rating of “Hold” and a consensus price target of $54.00.
Shares of Sanofi (NYSE:SNY) traded up 0.0421% on Thursday, hitting $48.5304. The stock had a trading volume of 37,503 shares. The company’s 50 day moving average price is $48.26 and its 200-day moving average price is $47.26. The company has a market cap of $121.88 billion, a P/E ratio of 11.5604 and a beta of 0.88. Sanofi has a 12 month low of $36.81 and a 12 month high of $50.24.
Sanofi (NYSE:SNY) last announced its quarterly earnings results on Monday, July 31st. The company reported $0.74 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.74. Sanofi had a return on equity of 25.34% and a net margin of 25.89%. The business had revenue of $8.66 billion for the quarter, compared to the consensus estimate of $8.71 billion. Sanofi’s quarterly revenue was down 2.3% compared to the same quarter last year. On average, analysts expect that Sanofi will post $3.34 earnings per share for the current year.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NYSE:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.